Agentic Workflow for Biotechnology Sequence and Method of Use Discovery

This workflow automates the high-stakes bottleneck of converting raw R&D signals into defensible IP assets. It systematically ingests sequence data from LIMS/ELN systems, assay results, and internal research papers, using specialized agents to parse biological entities and correlate findings. The operational upside comes from capturing latent inventions before publication or internal obsolescence, protecting R&D investment and creating a systematic, auditable process that replaces sporadic scientist recall and manual triage.

Implementation integrates with bioinformatics platforms via API and uses retrieval-augmented generation (RAG) over specialized corpora for prior art analysis. The architecture requires governance controls for confidence thresholds, mandatory human review for borderline cases, and immutable audit trails linking source data to draft claims. Rollout is sequenced by therapeutic area, with validation against historical patent filings to calibrate agent precision and recall before full production deployment.

This workflow automates the high-stakes, time-sensitive process of capturing biotech IP by scanning internal genomic sequence data, assay results, and research papers. It identifies patentable sequences (DNA, RNA, protein) and novel methods of use, directly addressing the bottleneck of manual review by scientists and patent counsel. The operational upside comes from shortening invention-to-filing cycles from months to weeks, preventing loss of valuable IP to competitors or prior art, and systematically leveraging R&D investment. Savings are realized through reduced legal consultation cycles and higher-quality, data-driven filing decisions.

Implementation integrates with bioinformatics platforms (e.g., Benchling), Laboratory Information Management Systems (LIMS), and enterprise legal management tools like Anaqua. The architecture requires robust controls: human-in-the-loop approval gates for novelty assessments, confidence scoring for agent outputs, and immutable audit trails for chain of custody. Exception routing handles ambiguous biological data or conflicting prior art, escalating to domain experts. Rollout is sequenced by therapeutic area or research team, with monitoring focused on agent accuracy, processing latency, and the conversion rate of R&D signals to filed applications.

This workflow automates the high-stakes, time-sensitive process of discovering patentable biological IP from fragmented R&D data. It eliminates the manual bottleneck of scientists and IP attorneys manually sifting through genomic sequences (DNA, RNA, protein), assay outputs, and research papers to identify novel inventions. The operational upside comes from shortening the invention capture cycle from months to weeks, reducing missed filing opportunities, and systematically converting R&D investment into defensible IP assets. Implementation requires orchestrating specialized agents for data ingestion, semantic search against databases like GenBank and PDB, and novelty scoring against global patent prior art.

The architecture integrates with enterprise systems, requiring controls for data quality from LIMS/ELNs, exception routing for low-confidence findings, and mandatory human review gates before filing. Deployment involves containerized agents, a central orchestrator like LangGraph, and secure APIs to bioinformatics platforms and docketing software (e.g., Anaqua, CPA Global). Governance mandates audit trails for inventorship determination and chain-of-custody documentation to support litigation readiness. This custom build transforms IP discovery from a reactive, manual process into a continuous, operationalized capability that protects R&D margin.

This workflow automates the high-stakes, manual bottleneck of identifying patentable biotech IP from complex, unstructured data sources. It continuously scans internal genomic sequence files, assay results from LIMS like Benchling, and research publications to surface novel DNA, RNA, or protein sequences and associated methods of use. The operational upside comes from shortening the invention capture cycle from months to weeks, preventing loss of valuable IP to academic pre-prints or competitor filings, and drastically reducing the scientist and paralegal hours spent on manual evidence compilation and prior art comparison.

Implementation requires a multi-agent architecture, typically built on LangGraph or CrewAI, with specialized agents for sequence alignment, semantic search against patent corpora, and method-of-use extraction from experimental narratives. The workflow integrates via APIs with bioinformatics platforms (e.g., DNAnexus), ELN/LIMS, and docketing systems like Anaqua. Critical controls include confidence scoring for novelty assessments, automated routing to domain-expert scientists for review, and immutable audit trails for inventorship and prior art analysis to support legal defensibility during prosecution.

Effective governance begins by defining clear decision boundaries for the autonomous agents. The workflow must integrate with existing quality and document control systems, such as a Laboratory Information Management System (LIMS) or Electronic Lab Notebook (ELN), to ensure all source data for a potential invention is captured and versioned. Approval gates are mandated before any draft filing materials are generated, requiring sign-off from both the lead scientist and IP counsel. This control layer prevents over-automation in high-stakes legal processes and ensures human experts remain in the loop for novelty judgment and strategic filing decisions.

Phased rollout mitigates implementation risk. Phase 1 targets internal repository mining only, automating the scan of historical genomic data and assay results against internal prior art. Phase 2 introduces external database queries (e.g., GenBank, USPTO) with results routed to a human-in-the-loop review queue. The final phase activates full agentic drafting of method-of-use claims, but only for pre-approved technical domains. Each phase includes defined KPIs, such as reduction in invention capture cycle time and false positive rate for novelty scoring, monitored via a centralized observability dashboard that logs every agent action, data source, and approval decision for auditability.